AB | BC | MB | NB | NL | NS | NT | ON | PE | QC | SK | YT

News & Announcements

2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008

Aug | July | June | May | Apr | Mar | Feb | Jan

Advisory
August 09, 2016

Pharmascience Inc. voluntarily recalls one lot of pms-Atenolol 100 mg due to a labelling error

Health Canada is advising Canadians that Pharmascience Inc. has initiated a voluntary recall of one lot of pms-Atenolol 100 mg, used to treat cardiovascular conditions such as hypertension (high blood pressure), due to a labelling error. The lot (Lot: 495259) contains foil blister packs incorrectly labelled as pms-Atenolol 50 mg with the wrong Drug Identification Number (DIN). The information on the outer package is correct.

Health Canada Advisory

Advisory
August 02, 2016

Unauthorized health products seized from Next Level Fitness in Richmond and Surrey, B.C.

Health Canada is informing Canadians that two unauthorized health products were seized from Next Level Fitness in Richmond and in Surrey,BC. The products TRT (Testosterone Booster) and Freak'n Test (Testosterone Enhancer) were labelled to contain a prescription drug substance (L-dopa) that may pose serious health risks to Canadians.

Health Canada Advisory

Foreign Product Alert
August 02, 2016

Health Canada is advising Canadians not to use these foreign health products as they may pose a health risk. These products have been found by regulators in other countries to contain undeclared allergens and or undeclared drug ingredients. Prescription drugs should only be taken under the supervision of a health care practitioner.

These products are not authorized for sale in Canada and have not been found on the Canadian market, but they may have been brought into the country by travellers

[> More]

Health Product InfoWatch
August 02, 2016

The July issue of the Health Product InfoWatch published by Health Canada is now available. This monthly publication provides clinically relevant safety information on pharmaceuticals, biologics, medical devices and natural health products. Please consult the index for a complete listing of previous issues.

Health Canada Health Product InfoWatch

Health Product Risk Communication
August 02, 2016

Solu-Cortef (hydrocortisone sodium succinate for injection) 100 mg/2 mL single-dose Act-O-Vial - Recalled Lots due to Potential for Dosing Error - Pfizer Canada Inc.

Pfizer is recalling 8 lots of Solu-Cortef (hydrocortisone sodium succinate for injection) 100 mg/2 mL single-dose Act-O-Vial as a result of a labelling text error on the side panel of the carton which indicates that the reconstituted product contains 125 mg /mL hydrocortisone instead of 50 mg/mL. This could lead to a potential dosing error.

Health Canada Health Product Risk Communication

Health Product Risk Communication
August 02, 2016

ERWINASE (Erwinia L-asparaginase) - Replacement with UK Labelled Stock - Jazz Pharmaceuticals

During a routine visual inspection, particulate matter was observed bound to the stopper of some vials of ERWINASE (Batch CAMR-177). Vials of ERWINASE with visible particulate matter need to be discarded. To avoid a potential shortage of ERWINASE, Health Canada has facilitated the importation of 50 packs of UK-labelled product from the global Batch CAMR-177 as an interim measure. A standard 5-micron filter needle should be used to withdraw the reconstituted product from the UK-labelled product prior to administration.

Health Canada Health Product Risk Communication

Information Update
August 02, 2016

Health Canada advises Canadians not to use two Personnelle sunscreen lotions due to microbial contamination

Further to the communication issued on March 24, 2016, Health Canada is advising Canadians not to use an additional Personnelle sunscreen lotion (see below) because of microbial contamination. The affected sunscreen lotions were sold at Jean Coutu retail locations.

Health Canada Information Update

Information Update
August 02, 2016

New safety measures for prescription codeine and hydrocodone to further restrict use in children and adolescents

Health Canada is taking new action to improve the safe use of two prescription opioid drugs, codeine and hydrocodone, to help further address the rare but potentially life-threatening risk of breathing problems in children and adolescents.

Health Canada Information Update

Health Product Risk Communication
August 29, 2016

REVOLADE (eltrombopag) - Risk of Severe Hepatotoxicity - Novartis Pharma Canada Inc.

REVOLADE administration can cause severe hepatotoxicity and potentially fatal liver injury. Cases of severe drug-induced liver injury with REVOLADE have been reported in patients during clinical trials and post-marketing.

Health Canada Health Product Risk Communication

Health Product Risk Communication
August 17, 2016

ADEMPAS (riociguat) - New Contraindication for Patients with Pulmonary Hypertension Associated with Idiopathic Interstitial Pneumonias (PH-IIP) - Bayer Inc.

Patients with pulmonary hypertension associated with idiopathic interstitial pneumonias (PH-IIP)should not be treated with ADEMPAS. The RISE-IIP study, which was investigating the effects of ADEMPAS in patients with PH-IIP, has been terminated early due to an increased risk of mortality and serious adverse events among subjects with PH-IIP receiving ADEMPAS.

Health Canada Health Product Risk Communication

Health Product InfoWatch
August 29, 2016

The August issue of the Health Product InfoWatch published by Health Canada is now available. This monthly publication provides clinically relevant safety information on pharmaceuticals, biologics, medical devices and natural health products. Please consult the index for a complete listing of previous issues.

Foreign Product Alert
August 24, 2016

Health Canada is advising Canadians not to use these foreign health products as they may pose a health risk. These products have been found by regulators in other countries to contain undeclared drug ingredients. Prescription drugs should only be taken under the supervision of a health care practitioner.

These products are not authorized for sale in Canada and have not been found on the Canadian market, but they may have been brought into the country by travellers or purchased over the Internet.

[> More]

Information Update
August 03, 2016

Health Canada advises consumers not to use the unauthorized weight loss product, AlgoSlim, distributed via mail order by E Sélection

Health Canada is advising consumers not to use the weight loss product AlgoSlim, distributed via mail order by E Sélection. The package does not contain unauthorized AlgoSlim and instead contains an authorized product, Slite-T, from a lot that expired in June 2012.

Health Canada Information Update